Lexeo Therapeutics, Inc. (LXEO) Current Ratio
- Current ratio · latest quarter: Value 13.89×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 13.89× | Current assets / current liabilities. $217.91M ÷ $15.69M ≈ 13.89× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 217.91M USD | Assets, Current |
| Current obligations | 15.69M USD | Liabilities, Current |
| Cash and equivalents | 92.83M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 118.87M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 4.18M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $217.91M | $15.69M | $92.83M | $118.87M | (m) | (m) | $4.18M | (m) | 13.89× |
| 2026-03-31 | $200.86M | $14.19M | $71.77M | $121.28M | (m) | (m) | $3.33M | (m) | 14.16× |
| 2025-12-31 | $188.39M | $16.81M | $63.00M | $118.77M | (m) | (m) | $4.86M | (m) | 11.21× |
| 2025-09-30 | $127.79M | $17.27M | $41.00M | $81.77M | (m) | (m) | $4.66M | (m) | 7.40× |
| 2025-06-30 | $140.06M | $31.59M | $35.48M | $97.41M | (m) | (m) | $20.02M | (m) | 4.43× |
| 2025-03-31 | $105.27M | $30.82M | $28.91M | (m) | (m) | (m) | $11.98M | (m) | 3.42× |
| 2024-12-31 | $126.12M | $22.85M | $35.01M | $86.50M | (m) | (m) | $6.42M | (m) | 5.52× |
| 2024-09-30 | $159.46M | $26.82M | $157.02M | (m) | (m) | (m) | $8.44M | (m) | 5.95× |
| 2024-06-30 | $177.15M | $18.88M | $174.98M | (m) | (m) | (m) | $5.76M | (m) | 9.38× |
| 2024-03-31 | $198.09M | $21.63M | $195.06M | (m) | (m) | (m) | $4.30M | (m) | 9.16× |
| 2023-12-31 | $124.29M | $17.24M | $121.47M | (m) | (m) | (m) | $3.79M | (m) | 7.21× |
| 2023-09-30 | $38.87M | $23.04M | $35.45M | (m) | (m) | (m) | $2.65M | (m) | 1.69× |
| 2022-12-31 | $80.05M | $14.35M | $77.33M | (m) | (m) | (m) | $2.68M | (m) | 5.58× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |